News
The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation.
Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are overprescribing them and some patients are taking them in secret.
The US Food and Drug Administration (FDA) has instructed all GLP-1 drug-makers to update their warning labels to include the ...
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related ...
Viking Therapeutics, Inc. ( NASDAQ: VKTX) Q2 2025 Earnings Conference Call July 23, 2025 4:30 PM ET Brian Lian - President, CEO & Director Gregory Zante - Chief Financial Officer ...
Stopping anti-obesity medications leads to significant weight regain, starting as early as eight weeks and stabilizing by six ...
People who stop taking GLP-1 medications like Ozempic and Wegovy started to regain weight in a short amount of time, ...
A study from Florida State University uncovers biological and behavioral consequences of weight loss underlying binge-eating ...
Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...
With the sales of weight-loss drugs booming, India is now the epicentre of the global obesity treatment market, reports The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results